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TRICKS OF THE TRADE
Safety of switching from natalizumab straight 
into fingolimod in a group of JCV-positive 
patients with multiple sclerosis
Segurança na mudança direta de natalizumabe para fingolimode em um grupo de 
pacientes com esclerose múltipla e positivos para JCV  
Yara Dadalti Fragoso1, Soniza Vieira Alves-Leon2, Jefferson Becker3, Joseph Bruno Bidin Brooks1, Eber 
Castro Correa4, Alfredo Damasceno5, Paulo Diniz da Gama6, Rodrigo Assad da Gama6, Andre Palma da 
Cunha Matta7, Ernane Pires Maciel8,  Thereza Cristina d’Avila Winckler9
Natalizumab and fingolimod are both efficient and safe 
treatments when used at the appropriate time in multiple 
sclerosis (MS). Peculiarities regarding the safety aspects 
of these drugs make it ideal for them to be administered 
by physicians who are familiar with the potential adverse 
events and know how to avoid them. Natalizumab is an ef-
ficient drug for treating MS. This monoclonal antibody is 
used in the form of monthly infusions and has remarkable 
effects on the activity of the disease, such that it maintaining 
MS under control in a large majority of patients1. The major 
concern when using natalizumab for longer periods is the 
potential for development fatal progressive multifocal leu-
koencephalopathy (PML) in association with JCV+ status. 
Because of the risk of developing PML or due to suboptimal 
response to this treatment, some patients are withdrawn 
from natalizumab after a period of using it2. When natali-
zumab is withdrawn, there is a serious risk of severe disease 
reactivation3 and there are no specific protocols to follow 
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ABSTRACT
Objective: To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods: Prospective data 
on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results: After a median period of nine 
months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events 
were reported. Conclusion: Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on 
multiple sclerosis management, however, is essential for drug switching.
Keywords: multiple sclerosis; natalizumab; fingolimod hydrochloride; therapeutics.
RESUMO
Objetivo: Avaliar a segurança na mudança entre natalizumabe e fingolimode sem período de washout. Métodos: Dados prospectivos de 
25 pacientes positivos para vírus JC que tiveram sua medicação modificada foram coletados e analisados. Resultados: Após uma mediana 
de nove meses da troca de medicação, não havia aspectos de segurança a relatar. Os pacientes estavam com bom controle da doença e não 
foram relatados eventos adversos. Conclusão: Washout pode não ser necessário na prática diária para a mudança entre natalizumabe e 
fingolimode. No entanto, expertise no manejo de esclerose múltipla é essencial para esta troca entre medicações. 
Palavras-chave: esclerose múltipla; natalizumab; cloridrato de fingolimode; terapêutica.
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in this situation4. Fingolimod is considered to be the best 
alternative for patients who are ceasing to use natalizum-
ab5, but the washout period between the two drugs is still 
a matter of controversy. It is considered that patients who 
switch from natalizumab to another drug continue to run 
the risk of PML during the overlap period between the two 
drugs, since natalizumab takes 56 days6 to 200 days6 to be 
cleared out of the patient’s serum. Because of this overlap, 
caution has been recommended by panels of experts, par-
ticularly when the patient is JCV+7. After the initial recom-
mendations for a six-month washout period, other propos-
als emerged and there is now no doubt that the shorter the 
washout period is, the less the chance of disease reactiva-
tion will be7,8. In fact, shorter periods seem to have an even 
better effect on disease control without compromising safe-
ty9. At present, the recommendations are that there should 
be 8 to 12 weeks of washout between these drugs, and the 
rate of reactivation is still high in the literature. The aim of 
the present study is to provide data on 25 JCV+ patients 
who had four to eight weeks of washout period, without any 
drug given during this time.
METHODS
This study was approved by the Ethics Committee of 
Universidade Metropolitana de Santos, Brazil, under the 
Certification of Ethical Presentation and Approval (CAAE) 
no. 05669912.3.0000.5509. Data were collected prospectively 
from patients who ceased using natalizumab and started 
treatment with fingolimod, at all of the nine MS units par-
ticipating in this project. The period between the drugs was 
four to eight weeks ( from the time of the last infusion of na-
talizumab to the time of administration of the first capsule 
of fingolimod). No cases were lost to follow-up. This was an 
observational and open study, and every participating neu-
rologist took his/her own decision on how long the wash-
out should be (between four and eight weeks), considering 
that there were no specific guidelines to follow. Sample size 
was calculated as 23 patients aiming for 95% confidence 
and 5% error.
RESULTS
Twenty-five patients entered the study. There were 
20 females and 5 male subjects, with a median age of 40 years. 
All the patients were JCV+. The median duration of treatment 
with natalizumab had been 29 months (range: 10 to 55 months) 
at the time of the drug switch. For 15 patients, the first dose of 
fingolimod was administered at the time of completing four 
weeks since the last infusion of natalizumab. The median du-
ration of treatment with fingolimod was 13 months at the time 
when the data were collected (range: nine to 26 weeks).
The average time that elapsed between treatments was 
5.6 ± 2.0 weeks (median = four weeks). One patient had previ-
ously had tuberculosis and required maintenance of isoniazid 
treatment throughout natalizumab and fingolimod adminis-
tration. One patient suffered a fall followed by seizures, but no 
evidence of PML was observed. This patient later evolved to 
secondary progressive MS and is, at present, without immuno-
modulatory or immunosuppressive treatment. No other note-
worthy adverse events or specific features were observed. 
All patients showed complete control of the disease with-
out relapses, and without lesion enlargement or new lesions 
on MRI. Disability, as assessed by the expanded disability scale 
score (EDSS)10, was unaltered after the drug switch (average 
EDSS = 3.6 before the switch and 3.5 at the last consultation). 
DISCUSSION
Natalizumab is an excellent choice for treating highly ac-
tive MS, but it may be necessary to withdraw this treatment 
at a given point. Fingolimod is the best choice for the drug 
switch8. Expert recommendations that are not evidence-
based state that there must be a washout period of three to 
six months before fingolimod is started. The recurrence of 
disease activity among such patients undergoing long follow-
up periods has been very high9.
In conclusion, in order to control disease activity, a max-
imum interval of eight weeks between the two treatments 
seems to be a safe and efficient way of dealing with natali-
zumab withdrawal.
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